Maintaining Warp Speed: Policy Requirements for a Just-in-Time, Capability-Based, Scalable Medical Countermeasure Research and Development Enterprise

Affiliations

¹ Colin N. O'Leary is a PhD Candidate, Program in Virology, Harvard Medical School, Boston, MA.
² Julia Barnes-Weise, JD, CLP, is Executive Director, Global Health Innovation Alliance Accelerator, Durham, NC.
³ Kendall Hoyt, PhD, is an Assistant Professor, Department of Medicine, Geisel School of Medicine at Dartmouth, and Faculty Director, Pandemic Security Project, Dickey Center for International Understanding, Dartmouth College; both in Hanover, NH.
⁴ Margaret Bourdeaux, MD, MPH, is Research Director, Program in Global Public Policy, Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, and Faculty Fellow, Harvard Kennedy School Belfer Center for Science and International Affairs, Cambridge, MA.

Colin N O'Leary et al. Health Secur. 2023 Jul-Aug.

. 2023 Jul-Aug;21(4):272-279.

doi: 10.1089/hs.2022.0134. Epub 2023 May 18.

¹ Colin N. O'Leary is a PhD Candidate, Program in Virology, Harvard Medical School, Boston, MA.
² Julia Barnes-Weise, JD, CLP, is Executive Director, Global Health Innovation Alliance Accelerator, Durham, NC.
³ Kendall Hoyt, PhD, is an Assistant Professor, Department of Medicine, Geisel School of Medicine at Dartmouth, and Faculty Director, Pandemic Security Project, Dickey Center for International Understanding, Dartmouth College; both in Hanover, NH.
⁴ Margaret Bourdeaux, MD, MPH, is Research Director, Program in Global Public Policy, Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, and Faculty Fellow, Harvard Kennedy School Belfer Center for Science and International Affairs, Cambridge, MA.

No abstract available

Keywords: BioShield; Biodefense R&D; Medical countermeasures; Operation Warp Speed; PHEMCE; Pandemic preparedness.

References

1. Morens DM, Fauci AS. Emerging pandemic diseases: how we got to COVID-19. Cell. 2020;182(5):1077-1092. - PMC - PubMed
1. Biomedical Advanced Research and Development Authority (BARDA). FDA approvals, licensures & clearances for BARDA supported products. MedicalCountermeasures.gov. Accessed October 3, 2022. https://www.medicalcountermeasures.gov/barda/fdaapprovals/
1. Hoyt K, Hatchett R. Preparing for the next Zika. Nat Biotechnol. 2016;34(4):384-386. - PMC - PubMed
1. US Government Accountability Office. Operation Warp Speed: accelerated COVID-19 vaccine development status and efforts to address manufacturing challenges. Published February 11, 2021. Accessed October 3, 2022. https://www.gao.gov/products/gao-21-319
1. Adams B. Moderna gains BARDA Zika vax funding; closes $474M funding round. Fierce Biotech. September 7, 2016. Accessed October 3, 2022. https://www.fiercebiotech.com/biotech/moderna-gains-barda-zika-vax-fundi...